Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Cellular Biomedicine Acquires CAR-T Technology from China Hospital

publication date: Feb 9, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cellular Biomedicine Group, a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing. The two groups will form a partnership for further development of the products in China. The PLA Hospital has already conducted early clinical trials of the technology on CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer. The data from the Phase I and II trials is included in the deal. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login